dc.contributor.author | Sestak, I | |
dc.contributor.author | Martín, M | |
dc.contributor.author | Dubsky, P | |
dc.contributor.author | Kronenwett, R | |
dc.contributor.author | Rojo, F | |
dc.contributor.author | Cuzick, J | |
dc.contributor.author | Filipits, M | |
dc.contributor.author | Ruiz, A | |
dc.contributor.author | Gradishar, W | |
dc.contributor.author | Soliman, H | |
dc.contributor.author | Schwartzberg, L | |
dc.contributor.author | Buus, R | |
dc.contributor.author | Hlauschek, D | |
dc.contributor.author | Rodríguez-Lescure, A | |
dc.contributor.author | Gnant, M | |
dc.date.accessioned | 2019-05-29T08:45:38Z | |
dc.date.issued | 2019-07-01 | |
dc.identifier.citation | Breast cancer research and treatment, 2019, 176 (2), pp. 377 - 386 | |
dc.identifier.issn | 0167-6806 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3243 | |
dc.identifier.eissn | 1573-7217 | |
dc.identifier.doi | 10.1007/s10549-019-05226-8 | |
dc.description.abstract | PURPOSE: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free interval (DRFI) rates for those who received adjuvant endocrine therapy (ET) alone compared to those with chemotherapy plus endocrine therapy (ET + C). METHODS: A total of 3746 women were included in this joint analysis. 2630 patients received 5 years of ET alone (ABCSG-6/8, TransATAC) and 1116 patients received ET + C (GEICAM 2003-02/9906). The primary objective was to evaluate the ability of EPclin to provide an estimate of the 10-year DR rate as a continuous function of EPclin separately for ET alone and ET + C. Cox proportional hazard models were used for these analyses. RESULTS: EPclin was highly prognostic for DR in women who received ET alone (HR 2.79 (2.49-3.13), P < 0.0001) as well as in those who received ET + C (HR 2.27 (1.99-2.59), P < 0.0001). Women who received ET + C had significantly smaller increases in 10-year DR rates with the increasing EPclin score than those receiving ET alone (EPclin = 5; 12% ET + C vs. 20% ET alone). We observed a significant positive interaction between EPclin and treatment groups (P-interaction = 0.022). CONCLUSIONS: In this comparative non-randomised analysis, the rate of increase in DR with EPclin score was significantly reduced in women who received ET + C versus ET alone. Our indirect comparisons suggest that a high EPclin score can predict chemotherapy benefit in women with ER-positive, HER2-negative disease. | |
dc.format | Print-Electronic | |
dc.format.extent | 377 - 386 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Cyclophosphamide | |
dc.subject | Fluorouracil | |
dc.subject | Doxorubicin | |
dc.subject | Receptor, erbB-2 | |
dc.subject | Receptors, Estrogen | |
dc.subject | Antineoplastic Agents, Hormonal | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Prognosis | |
dc.subject | Treatment Outcome | |
dc.subject | Combined Modality Therapy | |
dc.subject | Chemotherapy, Adjuvant | |
dc.subject | Proportional Hazards Models | |
dc.subject | Risk Assessment | |
dc.subject | Retrospective Studies | |
dc.subject | Predictive Value of Tests | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Clinical Trials as Topic | |
dc.subject | Kaplan-Meier Estimate | |
dc.title | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-04-08 | |
rioxxterms.versionofrecord | 10.1007/s10549-019-05226-8 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2019-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Breast cancer research and treatment | |
pubs.issue | 2 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR | |
pubs.publication-status | Published | |
pubs.volume | 176 | |
pubs.embargo.terms | No embargo | |
dc.contributor.icrauthor | Buus, Richard | |